Radiopharmaceutical treatment methods and use
AssigneePOINT Biopharma Inc.
InventorsNeil FLESHNER, Jessica JENSEN, Joe MCCANN
Life of this patent
Estimating the term…
Abstract
In one aspect, therapeutic use, methods of treatment and kits comprising 177Lu-PSMA I&T are provided for subjects exhibiting prostate cancer progression following administration with one or more androgen receptor inhibitor agents.
Claims41
A method for treating a subject suffering from prostate cancer, wherein the subject (i) has exhibited prostate cancer progression during or after treatment with one or more androgen receptor inhibitor agents and (ii) is chemotherapy-naïve before treatment with the one or more androgen receptor inhibitor agents;
- said method comprising:
- administering to the subject an amount of a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA providing from a 4 to 10 Gbq dose at least four times, at four week or longer intervals between doses.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A kit, comprising:
- a pharmaceutical preparation of a complex of lutetium-177 and EuK-Sub-kf-iodo-y-DOTAGA suitable for intravenous administration to a subject, and in an amount sufficient to provide from a 4 to 10 Gbq dose;
- and
- a package insert containing instructions for use of the agent in the treatment of a subject exhibiting prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has previously been treated with androgen receptor (AR) pathway inhibition but which subject is taxane chemotherapy-naïve or taxane chemotherapy adverse.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.